Anti-CD137 antibodies and methods of use thereof

US11242385B2 · kind B2 · utility

Assignee

• Agenus Inc. · US

Inventors

• Yanping Xiao · Brookline, US
• Nicholas Stuart Wilson · Melbourne, AU
• Benjamin Maxime Morin · Somerville, US
• Mark A. Findeis · Belmont, US
• Cornelia Anne Mundt · Lörrach, DE
• Marc van Dijk · Bosch en Duin, NL
• Dhan Sidhartha Chand · Woburn, US
• David Adam Savitsky · Boxford, US
• Dennis John Underwood · Brookline, US
• Olga Ignatovich · Cambridge, GB

Key dates

• Filing date: Apr 12, 2018
• Grant date: Feb 8, 2022
• Expiry date: Nov 20, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/75
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.